NGM’s mission is to harness the power of complex biology with rigor and urgency

NGM’s mission is to harness the power of complex biology with rigor and urgency, translating it into life−changing medicines that improve patient outcomes. The company’s vision is to make enduring scientific contributions that enhance human life, driving advancements in the understanding and treatment of various diseases. NGM Biopharmaceuticals boasts a robust clinical pipeline with several promising candidates in various stages of development:NGM282: A leading candidate for the treatment of NASH and liver fibrosis, currently in advanced clinical trials.NGM621: A therapy targeting age related macular degeneration (AMD), aimed at preserving vision and preventing disease progression. NGM120: An investigational drug for cancer cachexia and other metabolic conditions associated with cancer, designed to improve patient quality of life and outcomes.